Fast Locator 2014-2015: Jubilant - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2014-2015: Jubilant


Jubilant HollisterStier

Description:
Jubilant HollisterStier Pharma Solutions is a global manufacturing service provider, able to aseptically fill liquid, lyophilized, semi-solid and solid dosage forms in our facilities across North America and India.  Jubilant HollisterStier Pharma Solutions represents the CMOs formally branded as HollisterStier Contract Manufacturing and Draxis Pharma, as well as non-branded solid dosage sites in Maryland and India. New branded name and logo,
same quality service. 

Quality is part of Jubilant HollisterStier's corporate culture and is held to a high standard throughout our facilities.  We provide a full-range of support and services to streamline the manufacturing process such as on-site assistance from process qualifications and regulatory submittals through product release. Jubilant HollisterStier’s Quality Unit maintains an integrated quality assurance program that emphasizes quality design, validation and proper use of facilities and equipment.

Certified Project Managers work with our clients and our expert staff throughout the manufacturing process to ensure that projects are processed efficiently and safely.  We are committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.

For more information about Jubilant HollisterStier Pharma Solutions, please visit HScontract.com.

Website:
www.HScontract.com

Services Provided:

Sterile Fill/FinishSpokane, WA
Phase I-commercial sterile injectables, lyophilization

Sterile and non-sterile Fill/FinishMontreal, Quebec, Canada
Commercial sterile injectables, lyophilization and opthalmics
Non-sterile topical creams/ointments and liquids

Small Volume- Commercial Solid DosageSalisbury, Maryland, USA
Tablets, capsules

Large Volume Solid DosageRoorkee, India
Tablets and capsules

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here